A Study of the Safety, Efficacy, & Pharmacokinetics of Tiragolumab in

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03639948` - Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer	Phase 2
Withdrawn	`NCT02427581` - Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy	Phase 1
Completed	`NCT01881230` - Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)	Phase 2/Phase 3
Completed	`NCT03652077` - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies	Phase 1
Terminated	`NCT01918306` - GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer	Phase 1/Phase 2
Recruiting	`NCT04914390` - A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer	Phase 2
Completed	`NCT03154749` - DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer	Phase 2
Completed	`NCT04504916` - A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002)	Phase 2
Completed	`NCT03345485` - Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT04582955` - Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy	N/A
Terminated	`NCT04099277` - A Study of LY3435151 in Participants With Solid Tumors	Phase 1
Withdrawn	`NCT01695057` - Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer	N/A
Terminated	`NCT01234532` - Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery	Phase 2
Recruiting	`NCT03805399` - FUSCC Refractory TNBC Umbrella (FUTURE)	Phase 1/Phase 2
Active, not recruiting	`NCT04129996` - A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)	Phase 2
Terminated	`NCT03621982` - Study of ADCT-301 in Patients With Selected Advanced Solid Tumors	Phase 1
Recruiting	`NCT05336721` - A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC	Phase 2
Terminated	`NCT03674827` - Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC	Phase 1
Completed	`NCT04177108` - A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer	Phase 3
Suspended	`NCT03002103` - A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer	Phase 3

NCT number	NCT04584112
Study type	Interventional
Source	Hoffmann-La Roche
Contact
Status	Completed
Phase	Phase 1
Start date	September 28, 2020
Completion date	March 8, 2023

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms